← Back to Clinical Trials
Recruiting NCT05782556

NCT05782556 Freiburg TIPS Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05782556
Status Recruiting
Phase
Sponsor University Hospital Freiburg
Condition Liver Cirrhosis
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2023-01-01
Primary Completion 2033-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 100 Years
Study Type OBSERVATIONAL
Interventions
Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2023-01-01 with a primary completion date of 2033-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Patients with clinically significant portal hypertension allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Medicine II of the University Medical Center Freiburg, Germany will be offered to participate in this prospective observational trial. Clinical and laboratory as well as outcome parameters will be assessed before and within the first 12 months after TIPS implantation following a regular follow-up schedule with clinical visits at the University Medical Center Freiburg. During follow-up visits, serum/plasma samples and peripheral blood mononuclear cells (PBMC) are collected and stored in a associated biobank.

Eligibility Criteria

Inclusion Criteria: * Patients allocated to TIPS implantation due to clinically significant cirrhotic and non-cirrhotic portal hypertension Exclusion Criteria: * Withdrawal of written informed consent

Contact & Investigator

Central Contact

Dominik Bettinger, MD

✉ dominik.bettinger@uniklinik-freiburg.de

📞 49761270-36870

Principal Investigator

Dominik Bettinger, MD

PRINCIPAL INVESTIGATOR

University Hospital Freiburg

Frequently Asked Questions

Who can join the NCT05782556 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Liver Cirrhosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05782556 currently recruiting?

Yes, NCT05782556 is actively recruiting participants. Contact the research team at dominik.bettinger@uniklinik-freiburg.de for enrollment information.

Where is the NCT05782556 trial being conducted?

This trial is being conducted at Freiburg im Breisgau, Germany.

Who is sponsoring the NCT05782556 clinical trial?

NCT05782556 is sponsored by University Hospital Freiburg. The principal investigator is Dominik Bettinger, MD at University Hospital Freiburg. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology